Format

Send to

Choose Destination
See comment in PubMed Commons below
Regen Med. 2013 Mar;8(2):227-32. doi: 10.2217/rme.13.5.

Understanding regenerative medicine: a commissioner's viewpoint.

Author information

1
Clinical Effectiveness, Bupa Corporate Centre Medical Team, Bupa House, 15 Bloomsbury Way, London WC1A 2BA, UK. warrenv@bupa.com

Abstract

Regenerative medicines (RMs) represent a relatively new mode of care. Commissioners of healthcare need a pragmatic method to identify RMs which are safe and that will, when delivered in the context of an appropriate care pathway, avoid premature death and reduce morbidity for patients. This article offers a way of distinguishing between those which are useful currently and those which are not, although they may be in the future. This information is set in the context of reflection on issues that experience has demonstrated to be relevant to funding RMs. This article is potentially useful to developers of RM products as well as to commissioners of care, as it demonstrates what information will be required for a key step towards the adoption of their product.

PMID:
23477402
DOI:
10.2217/rme.13.5
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center